Liminatus Pharma, Inc. Warrants
LIMNW$0.04 -0.03 (-40.87%)
Company News
Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Liminatus Pharma, a clinical-stage immuno-oncology company, has entered a Memorandum of Understanding with Capital Trust Group for a $30 million equity investment to support its research and development of advanced immunotherapy assets.
